The Icelandic DNA Behind Amgen’s Hunt for the Next Ozempic
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Þróun nýs megrunarlyfs úráská svároska opástirásins Amgen is based on research by scientists deCode á geneticefni close to two hundred thousand Icelanders. Bloomberg talks in detail about the development of the drug, which goes by the name MariTide and is intended to compete with similar drugs Eli Lilly and Novo, formerly known as Novo Nordisk. Amgen bought DeCode in 2012 and has used its genetic research to discover and develop new drugs. Almos…
The Icelandic DNA Behind Amgen’s Hunt for the Next Ozempic
Amgen's best chance at breaking into the high-stakes obesity drug market got its start in a basement at the University of Iceland Science Park in Reykjavík, in a freezer chilled to minus-13 degrees Fahrenheit. Bloomberg's Madison Muller explains. #iceland #ozempic #health #obesity #world #news…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
